Clinics in Dermatology
Volume 24, Issue 6 , Pages 509-520 , November 2006

Diagnosis, treatment, and prognosis of erythema migrans and Lyme arthritis

  • Henry M. Feder Jr, MD

      Affiliations

    • Division of Infectious Diseases, University of Connecticut Health Center, Farmington, CT 06030, USA
    • Department of Pediatrics, Connecticut Children's Medical Center, USA
    • Tel.: +1 860 679 2928; fax: +1 860 679 1350.
    • ,
  • Micha Abeles, MD

      Affiliations

    • Division of Rheumatology, University of Connecticut Health Center, Farmington, CT 06030, USA
    • Tel.: +1 860 679 2160; fax: +1 860 679 1287.
    • ,
  • Megan Bernstein, MD

      Affiliations

    • University of Connecticut Health Center, Farmington, CT 06030, USA
    • ,
  • Diane Whitaker-Worth, MD

      Affiliations

    • Department of Dermatology, University of Connecticut Health Center, Farmington, CT 06030, USA
    • Tel.: +1 860 679 3474; fax: +1 860 679 1267.
    • ,
  • Jane M. Grant-Kels, MD

      Affiliations

    • Department of Dermatology, University of Connecticut Health Center, Farmington, CT 06030, USA
    • Corresponding Author InformationCorresponding author. Tel.: +1 860 679 3474; fax: +1 860 679 1267.

References 

  1. Steere AC, Malawista SE, Snydman DR, et al. Lyme arthritis: an epidemic of oligoarticular arthritis in children and adults in three Connecticut communities. Arthritis Rheum. 1977;20:7–17
  2. Spielman A, Wilson ML, Levine JF, et al. Ecology of Ixodes dammini–borne human babesiosis and Lyme disease. Annu Rev Entomol. 1985;30:439–460
  3. Steere AC. Lyme disease. N Engl J Med. 2001;345:115–124
  4. Burgdorfer W, Barbour AG, Hayes SF, Benach JL, Grunwaldt E, Davis JP. Lyme disease—a tick-borne spirochetosis?. Science. 1982;216:1317–1319
  5. Steere AC, Grodzicki RL, Kornblatt AN, et al. The spirochetal etiology of Lyme disease. N Engl J Med. 1983;308:733–740
  6. Klempner MS, Hu LT, Evans J, et al. Two controlled trials of antibiotic treatment in patients with persistent symptoms and a history of Lyme disease. N Engl J Med. 2001;345:85–92
  7. Wormser GP, Nadelman RB, Dattwyler RJ, et al. Practice guidelines for the treatment of Lyme disease: the Infectious Diseases Society of America. Clin Infect Dis. 2000;31(Suppl 1):1–14
  8. Klempner MS, Schmid C, Hu L, et al. Intralaboratory reliability of serologic and urine testing for Lyme disease. Am J Med. 2001;110:217–219
  9. Dammin GJ. Erythema migrans: a chronicle. Rev Infect Dis. 1989;11:142–150
  10. Hellerstrom S. Erythema chronicum migrans Afzelius with meningitis. South Med J. 1950;43:330–334
  11. Scrimenti RJ. Erythema chronicum migrans. Arch Dermatol. 1970;102:104–105
  12. Mast WE, Barrows WM. Erythema chronicum migrans in the United States. JAMA. 1976;236:859–860
  13. Berger BW. Dermatologic manifestations of Lyme disease. Rev Infect Dis. 1989;2:51475–51481
  14. Malane MS, Grant-Kels JM, Feder HM, Luger SW. Diagnosis of Lyme disease based on dermatologic manifestations. Ann Intern Med. 1991;114:490–498
  15. Steere AC, Sikand VK, Meurice F, et al. Vaccination against Lyme disease with recombinant. Borrelia burgdorferi outer-surface lipoprotein A with adjuvant. N Engl J Med. 1998;339:209–215
  16. Smith RP, Schoen RT, Rahn DW, et al. Clinical characteristics and treatment outcome of early Lyme disease in patients with microbiologically confirmed erythema migrans. Ann Intern Med. 2002;136:421–428
  17. Sood SK, Salzman MB, Johnson BJ, et al. Duration of tick attachment as a predictor of risk of Lyme disease in an area in which Lyme disease is endemic. J Infect Dis. 1997;175:996–999
  18. Costello CM, Steere AC, Pinkerton RE, Feder HM. A prospective study of tick bites in an endemic area for Lyme disease. J Infect Dis. 1989;159:136–139
  19. Shapiro ED, Gerber MA, Holabird NB, et al. A controlled trial of antimicrobial prophylaxis for Lyme disease after deer tick bites. N Engl J Med. 1992;327:1769–1773
  20. Agre F, Schwartz R. The value of early treatment of deer tick bites for the prevention of Lyme disease. Am J Dis Child. 1993;147:945–947
  21. Nadelamn RB, Nowakowski J, Fish D, et al. Prophylaxis with single dose doxycycline for the prevention of Lyme disease after an Ixodes scapularis tick bite. N Engl J Med. 2001;345:79–84
  22. Murray T, Feder HM. Management of tick bites and early Lyme disease: a survey of Connecticut physician. Pediatrics. 2001;108:1367–1370
  23. Wormser GP, Masters E, Nowakowski J, et al. Prospective clinical evaluation of patients from Missouri and New York with erythema migrans–like skin lesions. Clin Infect Dis. 2005;41:958–965
  24. Stobierski MG, Hall WN, Robinson-Dunn B, Stiefel Shiflett H, Carlson V. Isolation of Borrelia burgdorferi from two patients in Michigan. Clin Infect Dis. 1994;19:944–946
  25. Feder HM, Hunt MS. Pitfalls in the diagnosis and treatment of Lyme disease in children. JAMA. 1995;274:66–68
  26. Feder HM, Gerber MA, Luger SW, Ryan RW. Persistence of serum antibodies to Borrelia burgdorferi in patients treated for Lyme disease. Clin Infect Dis. 1992;15:788–793
  27. Luger SW, Krauss E. Serologic tests for Lyme disease. Arch Intern Med. 1990;150:761–763
  28. Salazar JC, Pope CD, Sellati TJ, et al. Coevolution of markers of innate and adaptive immunity in skin and peripheral blood of patients with erythema migrans. J Immunol. 2003;171:2660–2670
  29. Notice to readers: caution regarding testing for Lyme disease. MMWR Morb Mortal Wkly Rep. 2005;54:125
  30. Dattwyler RJ, Volkman DJ, Conary SM, et al. Amoxicillin plus probenecid versus doxycycline for treatment of erythema migrans borreliosis. Lancet. 1990;336:1404–1406
  31. Nadelman RB, Luger SW, Frank E, et al. Comparison of cefuroxime axetil and doxycycline in the treatment of early Lyme disease. Ann Intern Med. 1992;117:273–280
  32. Luft BJ, Dattwyler RJ, Johnson RC, et al. Azithromycin compared with amoxicillin in the treatment of erythema migrans. Ann Intern Med. 1996;124:785–791
  33. Feder HM, Whitaker DL, Hoss DM. The truth about erythema migrans. Arch Deramatol. 1997;133:93–94
  34. Steere AC, Hutchinson GJ, Rahn DW, et al. Treatment of the early manifestations of Lyme disease. Ann Intern Med. 1983;99:22–26
  35. Wormser GP, Ramanathan R, Norakowski J, et al. Duration of antibiotic therapy for early Lyme disease. A randomized, double-blind, placebo-controlled trial. Ann Intern Med. 2003;138:697–704
  36. Steere AC. Duration of antibiotic therapy for Lyme disease. Ann Intern Med. 2003;138:761–762
  37. Gerber MA, Shapiro ED, Burke GS, Parcells VJ, Bell GL. Lyme Disease Study Group. Lyme disease in children in southern Connecticut. N Engl J Med. 1996;335:1270–1274
  38. Stricker RB, Johnson L, Harris N, Burrascano JJ. Inaccurate information about Lyme disease on the internet and reply Feder HM Jr. Ped Infect Dis J. 2005;24:577–579
  39. Feder HM. Differences are voiced by two “Lyme camps” at a Connecticut public hearing on insurance coverage of Lyme disease. Pediatrics. 2000;105:855–857
  40. Cooper JD, Feder HM. Inaccurate information about Lyme disease on the Internet. Pediatr Infect Dis J. 2004;23:1105–1108
  41. Asbrink E, Hovmark A. Early and late cutaneous manifestations in Ixodes-borne borreliosis (erythema migrans borreliosis, Lyme borreliosis). Ann N Y Acad Sci. 1988;539:4–15
  42. Arnez M, Pleterski-Rigler D, Ahcan J, Ruzic-Sabljic E, Strle F. Demographic features, clinical characteristics and laboratory findings in children with multiple erythema migrans lesions in Slovenia. Wien Klin Wochenschr. 2001;113:98–101
  43. Strle F, Pleterski-Rigler D, Stanek G, et al. Solitary borrelial lymphocytoma: report of 36 cases. Infection. 1992;20:201–206
  44. Hovmark A, Asbrink E, Olsson I. The spirochetal etiology of lymphadenosis benigna cutis solitaria. Acta Derm Venereol. 1986;66:479–484
  45. Weber K, Schierz G, Wilske B, Preac-Mursic B. European erythema migrans disease and related disorders. Yale J Biol Med. 1984;57:463–471
  46. Werth VP. Infectious diseases that affect the skin and joints: Lyme disease. In:  Sontheimer RD,  Provost TT editor. Cutaneous manifestations of rheumatic diseases. Baltimore: Williams and Wilkins; 1996;p. 294–298
  47. Duray PH, Steere AC. Clinical pathologic correlations of Lyme disease by stage. Ann NY Acad Sci. 1988;539:65–79
  48. Asbrink E. Cutaneous manifestations of Lyme borreliosis. Clinical definitions and differential diagnoses. Scand J Infect Dis. 1991;(Suppl 77):44–50
  49. Marsch WC, Mayet A, Wolter M. Cutaneous fibroses induced by Borrelia burgdorferi. Br J Dermatol. 1993;128:674–678
  50. Lavoie PE, Wilson AJ, Tuffanelli DL. Acrodermatitis chronica atrophicans with antecedent Lyme disease in a Californian. A case report. Zentralbl Bakteriol Mikrobiol Hyg. 1986;263:262–265
  51. Burgdorf WH, Worret WI, Schultka O. Acrodermatitis chronica atrophicans. Int J Dermatol. 1979;18:595–601
  52. Kindstrand E, Nilsson BY, Hovmark A, Pirskanen R, Asbrink E. Peripheral neuropathy in acrodermatitis chronica atrophicans—a late Borrelia manifestation. Acta Neurol Scand. 1997;95:338–345
  53. Bauer J, Leitz G, Palmedo G, Hügel H. Anetoderma: another facet of Lyme disease?. J Am Acad Dermatol. 2003;48:S86–S88
  54. Granter SR, Barnhill RL, Hewins ME, Duray PH. Identification of Borrelia burgdorferi in diffuse fasciitis with peripheral eosinophilia: borrelial fasciitis. JAMA. 1994;272:1283–1285
  55. Hashimoto Y, Takahashi H, Matsuo S, et al. Polymerase chain reaction of Borrelia burgdorferi flagellin gene in Shulman syndrome. Dermatology. 1996;192:136–139
  56. Mosconi S, Streit M, Brönimann M, Braathen LR. Eosinophilic fasciits (Shulman syndrome). Dermatology. 2002;205:204–206
  57. Abele DC, Bedingfield RB, Chandler FW, Given KS. Progressive facial hemiatrophy (Parry-Romberg syndrome) and borreliosis. J Am Acad Dermatol. 1990;22:531–533
  58. Sahin MT, Bariş S, Karaman A. Parry-Romberg syndrome: a possible association with borreliosis. J Eur Acad Dermatol Venereol. 2004;18:204–207
  59. Aberer E, Kollegger H, Kristoferitsch W, Stanek G. Neuroborreliosis in morphea and lichen sclerosus et atrophicus. J Am Acad Dermatol. 1988;19:820–825
  60. Breier F, Klade H, Stanek G, et al. Lymphoproliferative responses to Borrelia burgdorferi in circumscribed scleroderma. Br J Dermatol. 1996;134:285–291
  61. Alonso-Llamazares J, Persing DH, Anda P, Gibson LE, Rutledge BJ, Iglesias L. No evidence for Borrelia burgdorferi infection in lesions of morphea and lichen sclerosus et atrophicus in Spain. A prospective study and literature review. Acta Derm Venereol. 1997;77:299–304
  62. Raguin G, Boisnic S, Souteyrand P, et al. No evidence for a spirochetal origin of localized scleroderma. Br J Dermatol. 1992;127:218–220
  63. Schempp C, Bocklage H, Lange R, Kolmel HW, Orfanos CE, Gollnick H. Further evidence for Borrelia burgdorferi infection in morphea and lichen sclerosus et atrophicus confirmed by DNA amplification. J Invest Dermatol. 1993;100:717–720
  64. Weide B, Schittek B, Klyscz T, et al. Moprhoea is neither associated with features of Borrelia burgdorferi infection, nor is this agent detectable in lesion skin by polymerase chain reaction. Br J Dermatol. 2000;143:780–785
  65. Hoesly JM, Mertz LE, Winkelmann RK. Localized scleroderma (morphea) and antibody to Borrelia burgdorferi. J Am Acad Dermatol. 1987;17:455–458
  66. Akimoto S, Ishikawa O, Miyachi Y. The absence of antibodies against Borrelia burgdorferi in the sera of Japanese patients with localized scleroderma. J Rheumatol. 1996;23:573–574
  67. Ozkan S, Atabey N, Fetil E, Erkizan V, Gunes AT. Evidence for Borrelia burgdorferi in morphea and lichen sclerosus. Int J Dermatol. 2000;39:278
  68. Abele DC, Anders KH, Chandler FW. Benign lymphocytic infiltration (Jessner-Kanof): another manifestation of borreliosis?. J Am Acad Dermatol. 1989;21:795–797
  69. Cerio R, MacDonald DM. Benign cutaneous lymphoid infiltrates. J Cutan Pathol. 1985;12:442–452
  70. Wood GS, Kamath NV, Guitart J, et al. Absence of Borrelia burgdorferi DNA in cutaneous B-cell lymphomas from the United States. J Cutan Pathol. 2001;28:502–507
  71. Garbe C, Stein H, Dienemann D, Orfanos CE. Borrelia burgdorferi–associated cutaneous B-cell lymphoma: clinical and immunohistologic characterization of four cases. J Am Acad Dermatol. 1991;24:584–590
  72. Cerroni L, Zochling N, Putz B, Kerl H. Infection by Borrelia burgdorferi and cutaneous B-cell lymphoma. J Cutan Pathol. 1997;24:457–461
  73. Duray PH, Pincus G, Jaffe ES, Merino MJ. B-cell lymphoma associated with Borrelia burgdorferi infection in the United States. Mod Pathol. 2000;13:147
  74. Asbrink E, Hovmark A. Classification, geographic variations, and epidemiology of Lyme borreliosis. Clin Dermatol. 1993;11:353–357
  75. Lang J. Catching the bug: how scientists found the cause of Lyme disease. Conn Med. 1989;53:357–364
  76. Seidenberg KB, Leib ML. Orbital myositis with Lyme disease. Am J Ophthalmol. 1990;110:98
  77. Steere AC, Schoen RT, Taylor E. The clinical evolution of Lyme arthritis. Ann Intern Med. 1987;107:726–731
  78. Gerber MA, Zemel LS, Shapiro ED. Lyme arthritis in children: clinical epidemiology and long-term outcomes. Pediatrics. 1998;102:905–908
  79. Steere AC, Malawista SE, Snyderman DR, et al. Erythema chronicum migrans and Lyme arthritis. The enlarging clinical spectrum. Ann Intern Med. 1977;86:685–698
  80. Zemel L. Lyme disease—a pediatric perspective. J Rheumatol. 1992;19(S34):1–13
  81. Szer IS, Taylor E, Steere AC. The long-term course of Lyme arthritis in children. N Engl J Med. 1991;325:159–163
  82. Bentas W, Karch H, Huppertz H-I. Lyme arthritis in children and adolescents: outcome 12 months after initiation of antibiotic therapy. J Rheumatol. 2000;27:2025–2030
  83. Steere AC, Gross D, Meyer ET, Huber BT. Autoimmune mechanisms in antibiotic treatment-resistant Lyme arthritis. J Autoimmun. 2001;16:2263–2268
  84. Gross DM, Forsthuber T, Tary-Lehmann M, et al. Identification of LFA-1 as a candidate autoantigen in treatment-resistant Lyme arthritis. Science. 1998;281:703–706
  85. Steere AC, Falk B, Drouin EE, Baxter-Lowe A, Hammer J, Nepom GT. Binding of outer surface protein A and human lymphocyte function-associated antigen 1 peptides to HLA-DR molecules associated with antibiotic treatment-resistant Lyme arthritis. Arthritis Rheum. 2003;48:534–540
  86. Nocton JJ, Dressler F, Rutledge BJ, Rys PN, Persing DH, Steere AC. Detection of Borrelia burgdorferi DNA by polymerase chain reaction in synovial fluid from patients with Lyme arthritis. N Engl J Med. 1994;330:229–234
  87. Carlson D, et al. Lack of Borrelia burgdorferi DNA in synovial samples in patients with antibiotic treatment-resistant Lyme arthritis. Arthritis Rheum. 1999;42:2705–2709
  88. Maier B, Molinger M, Cope AP, et al. Multiple cross-reactive self ligands for Borrelia burgdorferi–specific HLA-DR4 restricted T cells. Eur J Immunol. 2000;30:448–457
  89. Aguero-Rosenfeld ME, Wang G, Schwartz I, Wormser GP. Diagnosis of Lyme borreliosis. Clin Microbiol Rev. 2005;18:484–509
  90. Ruzic-Sabljic E. Microbiological diagnosis of Lyme borreliosis. Acta Dermatoven APA. 2001;10:4
  91. Franz JK, Fritze O, Rittig M, et al. Insights from a novel three-dimensional in vitro model of Lyme arthritis. Arthritis Rheum. 2003;44:151–162
  92. Johnston VE, Duray PH, Steere AC, et al. Lyme arthritis. Spirochetes found in synovial microangiopathic lesions. Am J Pathol. 1985;118:26–34
  93. Hendrickx G, De Boeck H, Goossens A, Demanet C, Vandenplas Y. Persistent synovitis in children with Lyme arthritis: two unusual cases. An immunogenetic approach. Eur J Pediatr. 2004;163:646–650
  94. Jaulhac B, Chary-Valckenaere I, Sibilia J, et al. Detection of Borrelia burgdorferi by DNA amplification in synovial tissue samples from patients with Lyme arthritis. Arthritis Rheum. 1996;39:736–745
  95. Mclaughlin TP, Zemel L, Fisher RL, Gossling HR. Chronic arthritis of the knee in Lyme disease. Review of the literature and report of two cases treated by synovectomy. J Bone Joint Surg. 1986;68A:1057–1061
  96. Schoen RT, Aversa JM, Rahn DW, Steere AC. Treatment of refractory chronic Lyme arthritis with arthroscopic synovectomy. Arthrits Rheum. 1991;34:1056–1060
  97. Traverse W, Lakshminarayanan S. Radiosynovectomy for recurrent Lyme arthropathy. Arthritis Rheum. 2005;F104–F598
  98. Straubinger RK. PCR-based quantification of Borrelia burgdorferi organisms in canine tissues over a 500 day postinfection period. J Clin Microbiol. 2000;38:2191–2199
  99. Saldziene A, Rosa PA, Thompson PA, Hogan DM, Barbour AG. Antibody-resistant mutants of Borrelia burgdorferi: in vitro selection and characterization. J Exp Med. 1992;176:799–809
  100. Fawcett PT, Rose CD, Maduskuie VL, et al. Patients with antibiotic resistant Lyme arthritis have elevated synovial levels of TNF alpha. Arthritis Rheum. 2005;S172
  101. Reimers CD, de Koning J, Neubert U, et al. Borrelia burgdorferi myositis: report of eight patients. J Neurol. 1993;240:278–283
  102. Atlas E, Novak SN, Duray PH, Steere AC. Lyme myositis: muscle invasion by Borrelia burgdorferi. Ann Intern Med. 1988;109:245–246
  103. Horowitz HW, Sanghera K, Goldberg N, et al. Dermatomyositis associated with Lyme disease: case report and review of Lyme myositis. Clin Infect Dis. 1994;18:166–171
  104. Wormser GP, Nadelman RB, Dattwyler RJ, et al. Practice guidelines for the treatment of Lyme disease. Clin Infect Dis. 2000;31(Suppl):S1–S14
  105. Sigal LH. Persisting complaints attributed to chronic Lyme disease: possible mechanisms and implications for management. Am J Med. 1994;96:365–374
  106. Dinerman H, Steere AC. Lyme disease associated with fibromyalgia. Ann Intern Med. 1992;117:281–285
  107. Sigal LH. Misconceptions about Lyme disease: confusions hiding behind ill-chosen terminology. Ann Intern Med. 2002;136:413–419
  108. Klempner MS, Hu LT, Evans J, et al. Two controlled trials of antibiotic treatment in patients with persistent symptoms and a history of Lyme disease. N Engl J Med. 2001;345:85–92
  109. Kaplan RF, Trevino RP, Johnson GM, et al. Cognitive function in post-treatment Lyme disease: do additional antibiotics help?. Neurology. 2003;60:1916–1922
  110. Krupp LB, Hyman LG, Grimson R, et al. Study and treatment of post Lyme disease (STOP-LD). A randomized double masked clinical trial. Neurology. 2003;60:1923–1930
  111. Radolf J. Posttreatment chronic Lyme disease—what it is not. J Infect Dis. 2005;192:948–949
  112. Steiner I. Treating post Lyme disease: trying to solve one equation with too many unknowns. Neurology. 2003;60:1888–1889

PII: S0738-081X(06)00105-2

doi: 10.1016/j.clindermatol.2006.07.012

Clinics in Dermatology
Volume 24, Issue 6 , Pages 509-520 , November 2006

Article Tools

* Image Usage & Resolution